Controversia en el uso y en la financiación de SYSADOA para la osteoartritis en España: un análisis del debate científico-social en los medios de comunicación

IF 16.4 1区化学 Q1 CHEMISTRY, MULTIDISCIPLINARY

Accounts of Chemical Research Pub Date : 2024-10-01 DOI:10.1016/j.reuma.2024.05.002

Pedro Alfonso Domínguez Vera , Luis Carrasco Páez

{"title":"Controversia en el uso y en la financiación de SYSADOA para la osteoartritis en España: un análisis del debate científico-social en los medios de comunicación","authors":"Pedro Alfonso Domínguez Vera , Luis Carrasco Páez","doi":"10.1016/j.reuma.2024.05.002","DOIUrl":null,"url":null,"abstract":"<div><h3>Background and objective</h3><div>The use of SYmptomatic Slow-Acting Drugs for Osteoarthritis (SYSADOA) in the treatment of osteoarthritis (OA) has been a topic of debate in the scientific community and public entities regarding their public financing in Spain. The objective of this study was to describe and analyze the main positions of media outlets, public entities, regarding the use and financing of SYSADOA in Spain.</div></div><div><h3>Methods</h3><div>A qualitative and quantitative analysis of the content regarding the use and financing of SYSADOA was conducted in general media outlets (<em>El País</em>, <em>El Mundo, La Vanguardia, ABC,</em> and <em>20minutos</em>), public statements, and Twitter® publications.</div></div><div><h3>Results</h3><div>A total of 15 articles in general media outlets, 872 tweets, and 7 public entity statements were identified. Mostly, media outlets (91%) and social media platforms (78%) exhibited a favorable trend towards funding.</div></div><div><h3>Discussion and conclusions</h3><div>The use of SYSADOA in OA patients continues to be controversial in the scientific community. However, there is consensus among patient associations in favor of public funding and use as a treatment for OA patients.</div></div>","PeriodicalId":1,"journal":{"name":"Accounts of Chemical Research","volume":null,"pages":null},"PeriodicalIF":16.4000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Accounts of Chemical Research","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1699258X24000494","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}

引用次数: 0

Abstract

Background and objective

The use of SYmptomatic Slow-Acting Drugs for Osteoarthritis (SYSADOA) in the treatment of osteoarthritis (OA) has been a topic of debate in the scientific community and public entities regarding their public financing in Spain. The objective of this study was to describe and analyze the main positions of media outlets, public entities, regarding the use and financing of SYSADOA in Spain.

Methods

A qualitative and quantitative analysis of the content regarding the use and financing of SYSADOA was conducted in general media outlets (El País, El Mundo, La Vanguardia, ABC, and 20minutos), public statements, and Twitter® publications.

Results

A total of 15 articles in general media outlets, 872 tweets, and 7 public entity statements were identified. Mostly, media outlets (91%) and social media platforms (78%) exhibited a favorable trend towards funding.

Discussion and conclusions

The use of SYSADOA in OA patients continues to be controversial in the scientific community. However, there is consensus among patient associations in favor of public funding and use as a treatment for OA patients.

查看原文本刊更多论文

西班牙骨关节炎使用和资助 SYSADOA 的争议：媒体社会科学辩论分析

背景和目的在西班牙，骨关节炎慢作用药物 SYSADOA（SYmptomatic Slow-Acting Drugs for Osteoarthritis）在治疗骨关节炎（OA）方面的应用一直是科学界和公共实体就其公共融资问题争论不休的话题。本研究旨在描述和分析媒体、公共实体对西班牙使用和资助 SYSADOA 的主要立场。研究方法对一般媒体（El País、El Mundo、La Vanguardia、ABC 和 20minutos）、公共声明和 Twitter® 出版物中有关 SYSADOA 使用和资助的内容进行了定性和定量分析。结果共发现 15 篇一般媒体文章、872 条微博和 7 份公共实体声明。大多数媒体（91%）和社交媒体平台（78%）对资助表现出了积极的趋势。讨论与结论在 OA 患者中使用 SYSADOA 在科学界仍存在争议。然而，患者协会已达成共识，赞成公共资助并将其用作治疗 OA 患者的方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Accounts of Chemical Research 化学-化学综合

CiteScore

31.40

自引率

1.10%

发文量

312

审稿时长

2 months

期刊介绍： Accounts of Chemical Research presents short, concise and critical articles offering easy-to-read overviews of basic research and applications in all areas of chemistry and biochemistry. These short reviews focus on research from the author’s own laboratory and are designed to teach the reader about a research project. In addition, Accounts of Chemical Research publishes commentaries that give an informed opinion on a current research problem. Special Issues online are devoted to a single topic of unusual activity and significance. Accounts of Chemical Research replaces the traditional article abstract with an article "Conspectus." These entries synopsize the research affording the reader a closer look at the content and significance of an article. Through this provision of a more detailed description of the article contents, the Conspectus enhances the article's discoverability by search engines and the exposure for the research.